Category Archives: Biotech

US and Europe At Risk from Substandard Medicines

By Julian Upton | Published: February 25, 2010
Guest blog by Helen Disney, Chief Executive and Founder of the Stockholm Network, a pan-European think tank. When most of us look at taking a new medicine we tend to think it will make us better. Some of us may think about possible side effects but few of us expect the medicines we take to actually [...]
Also posted in Emerging Markets, Europe, Global, Guest Blog, Regulatory, Safety | Tagged , , , , , , , , , , , | Leave a comment

Roche and Genentech Seal the Deal
for $46.8 Billion

By George Koroneos | Published: March 12, 2009
After months and months of back and forth over the true value of Genentech, Roche finally got the good news it’s been looking for: Genentech’s board of directors, this morning, approved Roche’s latest offer of $46.8 billion ($95 per share) to acquire all shares of the biotech giant. Roche plans to keep the Genentech site in [...]
Posted in Biotech | Tagged , , , , , , | 1 Comment

Acorda Seeking NDA for MS Drug

By Cassandra Blohowiak | Published: February 27, 2009
Hawthorne, NY-based Acorda Therapeutics yesterday released Phase III clinical trial data of fampridine-SR, a novel treatment that improves walking ability in Multiple Sclerosis patients. Acorda filed a New Drug Application for fampridine on January 30, and FDA approval is expected in about 10 months. If green-lighted, fampridine will be the first drug approved with the indication [...]
Posted in Biotech | Tagged , , | Leave a comment

Gilead Making a Bundle

By Walter Armstrong | Published: February 10, 2009
Gilead Sciences has once again proven that independent biotechs can innovate with the best of Big Pharma. The Silicon Valley company’s wizardry at weaving multiple drugs into a single weft enabled it to overthrow GlaxoSmithKline as king of HIV in 2007. Yesterday, at the 16th annual Congress of Retroviruses and Opportunistic Infections (CROI), the biotech [...]
Also posted in Emerging Markets, R&D | Tagged , , , | Leave a comment

Lilly Puts Up $6.5 Billion for ImClone

By George Koroneos | Published: October 6, 2008
Lilly broke the news Monday morning that ImClone had accepted its offer to acquire the biotech firm for $6.5 billion or $70 per share—Lilly’s largest acquisition ever. With this purchase Lilly gains control of ImClone’s blockbuster, targeted cancer agent Erbitux, which is marketed for second- and third-line colon cancer and refractory head and neck cancer. ImClone also [...]
Also posted in Deals | Tagged , , , , , , , , | 1 Comment